CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Previous close
$44.42
−$0.69 · -1.53%
Regular session · ET · Market data may be delayed.
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Day range
Current $44.42
52-week range
Current $44.42
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
81
Deep Value
Sentiment
62
Bullish
Risk
56
Elevated Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Day range
Current $44.42
52-week range
Current $44.42
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.37B USD | 1.31B USD | 1.24B USD | 1.05B USD | 1.01B USD |
| Cost of goods sold | 649.12M USD | 573.98M USD | 568.5M USD | 474.23M USD | 442.6M USD |
| Gross profit | 725.38M USD | 733.03M USD | 676.25M USD | 571.25M USD | 568.04M USD |
| Research and development | 55.88M USD | 54.43M USD | 52.6M USD | 47.15M USD | 43.57M USD |
| Selling, general, and administrative | 528.36M USD | 478.28M USD | 503.04M USD | 454.04M USD | 414.75M USD |
| Operating expenses | 584.24M USD | 532.71M USD | 555.64M USD | 501.19M USD | 458.32M USD |
| Interest expense | 31.09M USD | 37.3M USD | 39.78M USD | 28.91M USD | 35.49M USD |
| Depreciation and amortization | 74.28M USD | 51.31M USD | 51.4M USD | 69.52M USD | 70.74M USD |
| Operating income | 141.13M USD | 200.33M USD | 120.6M USD | 70.05M USD | 109.72M USD |
| Net income | 47.06M USD | 132.42M USD | 64.46M USD | −80.58M USD | 62.54M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$37.50
15.58% downsidePrice history unavailable
High $39.00Average $37.50Low $36.00Cash distributions grouped by calendar year; partial years are marked.
$0.80
2024 complete year0.0% since 2020
$0.80
2,020
$0.80
2,021
$0.80
2,022
$0.80
2,023
$0.80
2,024
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Sep 15, 2025 | $0.20Quarterly | Sep 15, 2025 | Oct 3, 2025 |
Dividend | Jun 13, 2025 | $0.20Quarterly | Jun 13, 2025 | Jul 3, 2025 |
Dividend | Mar 14, 2025 | $0.20Quarterly | Mar 14, 2025 | Apr 4, 2025 |
Dividend | Dec 20, 2024 | $0.20Quarterly | Dec 20, 2024 | Jan 3, 2025 |
Dividend | Sep 16, 2024 | $0.20Quarterly | Sep 16, 2024 | Oct 4, 2024 |
Dividend | Jun 14, 2024 | $0.20Quarterly | Jun 14, 2024 | Jul 5, 2024 |
Ex-dividend Sep 15, 2025
$0.20
Quarterly
Record Sep 15, 2025 · Payment Oct 3, 2025
Ex-dividend Jun 13, 2025
$0.20
Quarterly
Record Jun 13, 2025 · Payment Jul 3, 2025
Ex-dividend Mar 14, 2025
$0.20
Quarterly
Record Mar 14, 2025 · Payment Apr 4, 2025
Ex-dividend Dec 20, 2024
$0.20
Quarterly
Record Dec 20, 2024 · Payment Jan 3, 2025
Ex-dividend Sep 16, 2024
$0.20
Quarterly
Record Sep 16, 2024 · Payment Oct 4, 2024
Ex-dividend Jun 14, 2024
$0.20
Quarterly
Record Jun 14, 2024 · Payment Jul 5, 2024
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.